SERGEF

Across TCGA pan-cancer cohorts, SERGEF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SERGEF data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SERGEF mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SERGEF expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where SERGEF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.994	0.806	<.001	53	view →
LUAD	DFS	Median	All	0.887	0.462	.002	33	view →
HNSC	OS	Median	All	1.000	0.960	.026	10	view →
GBM	OS	Median	All	0.272	0.498	.009	4	view →
LSCC	DFS	Median	II,III,IV	0.451	0.877	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SERGEF–PDAC (OS)

Open the PDAC breakdown →